Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial
Abstract
Opioid use disorder (OUD) continues to be a significant public health concern. Medications for OUD (MOUD) such as buprenorphine reduce overdose mortality, but relapses occur often, leading to adverse outcomes. Preliminary data suggest that cannabidiol (CBD) may be a potential adjunctive treatment to MOUD by attenuating cue-reactivity. This pilot study sought to evaluate the impact of a single dose of CBD on reward- and stress-related neurocognitive processes implicated in relapse among those with OUD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 30, 2023
- Source ID
- 10.3389/fpsyt.2023.1155984
Entities
People
- Joji Suzuki
- Peter R Chai
- Primavera A. Spagnolo
- Roger D. Weiss
- Ruth E. Tenenbaum
- Saeed Ahmed
- Sara Prostko
- Veronica Szpak
Organizations
- Defense Advanced Research Projects Agency
- National Institutes of Health